Buisson A, Nachury M, Bazoge M, Yzet C, et al. Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH-LT study. Aliment Pharmacol Ther 2023 Nov 30. doi: 10.1111/apt.17822.
PMID: 38037279